CLEAR Outcomes
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.
N
13.970
Design
Double-blind RCT
Endpunkt
CV death, MI, stroke or coronary revascularisation
Relevanz
2
Ergebnis11.7 % vs 13.3 % (HR 0.87); no new-onset diabetes; gout and tendon-rupture signals.
Nissen SE, et al. N Engl J Med. 2023;388(15):1353-1364. 10.1056/NEJMoa2215024
Diskussion & Kritik
Provides an outcomes-proven non-statin oral option for the genuinely statin-intolerant. The effect size is modest; the primary-prevention subgroup did better.